Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestor.lilly.com
Eli Lilly and Company News Releases
Get the latest updates from Eli Lilly and Company News Releases directly as they happen.
Follow now 261 followers
Latest posts
Last updated 1 day ago
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy
1 day ago
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically...
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
3 days ago
In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with...
Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
3 days ago
INDIANAPOLIS , Aug. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY)...
Lilly to participate in Wells Fargo 20th Annual Healthcare Conference
6 days ago
INDIANAPOLIS , Aug. 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY)...
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
8 days ago
INDIANAPOLIS , Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE...
Statement: America’s leading role in biopharmaceutical innovation
14 days ago
Lilly supports the administration’s goal of keeping the United States the world’s...
Lilly launches "The Court Is Hers™" to help more girls get in the game
19 days ago
Through partnerships with the Indiana Fever and the YMCA of Greater Indianapolis...
Lilly reports second-quarter 2025 financial results and raises guidance
22 days ago
Revenue in Q2 2025 increased 38% to $15.56 billion driven by volume...
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
22 days ago
In ATTAIN-1, the investigational once-daily oral pill showed significant efficacy, and a...
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
29 days ago
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8%...
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
30 days ago
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to...
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
about 1 month ago
Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with...